Browsing: Clinical Trials & R&D

Agios Pyrukynd results show mixed outcomes in a crucial sickle cell study, affecting the drug’s commercial outlook.

Roche giredestrant study demonstrates significant benefits in early breast cancer, marking a milestone with its oral SERD in the adjuvant setting.

Merck Winrevair heart study demonstrates significant improvement in blood flow for heart failure patients.

Ascletis weight loss drug ASC47 shows over 56% greater body weight reduction when combined with semaglutide in obesity treatment.

FDA pig organ trial to start next year, advancing gene-edited organs in humans. Key step in transplantation.

Sanofi stock drop over 10% after Amlitelimab Phase III results raises concerns about future pipeline and Dupixent patent expiration.

Merck ADC lung cancer treatment shows nearly 50% tumor shrinkage in mid-stage trial, heading to FDA.

Treeline Biosciences, a biotech company founded by Loxo Oncology’s Josh Bilenker and former Novartis executive Jeff Engelman, has announced the advancement of three cancer drugs into Phase 1 clinical trials. This development is supported by a substantial $200 million……

A biotech co-founded by Nobel laureate David Baker has reeled in an $80 million Series B to get into the clinic early next year with an AI-designed cancer drug.

Alnylam Pharmaceuticals said it will start a Phase 3 cardiovascular outcomes trial of its hypertension therapy zilebesiran this year, despite data showing the drug failed in a mid-stage study.